ESR1 and breast cancer: Another study which enrolled 11 metastatic ER+ breast cancer patients with exposure to serial endocrine therapies, identified that over half of these patient’s metastatic samples harbored ESR1 mutations localized in the LBD, that included Y537S, Y537C, Y537N, D538G, and L536Q mutations[55].